title: Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man. A double-blind cross-over study.
abstract: In a double-blind cross-over study we compared pituitary and methionine-free biosynthetic human growth hormone (P-hGH and B-hGH) with respect to pharmacokinetics and short-term metabolic effects in 9 hypopituitary children. They treated themselves for 4 weeks with 2 IU sc daily at 20.00 h. After admittance to hospital 2 IU was given: im the first day, and sc the second. They then switched over to the alternative preparation. The serum profiles of B- and P-hGH were identical. Comparing im and sc absorption, the latter was slower and resulted in smaller areas under the curves, indicating greater local degradation. Both preparations caused identical increases in somatomedin-C, but slightly more sustained after sc injection. Plasma glucose, plasma glucagon, and serum insulin fluctuated within normal ranges. The glucose profile pointed at a modest anti-insulin effect of hGH when given in the morning. The concentration in the blood of lactate, alanine, glycerol and B-OH-butyrate, and in serum of triglyceride, cholesterol and carbamide revealed no abnormalities with either hGH preparation. Finally, no development of anti-GH or E. coli polypeptide antibodies was seen. In conclusion, the pharmacokinetics and short-term metabolic effects of B-hGH and P-hGH were identical.
authors.affiliation: Institute of Experimental Clinical Research, Second University Clinic of Internal Medicine, Aarhus, Denmark.
authors.forename: J O
authors.initials: JO
authors.lastname: Jørgensen
authors.forename: A
authors.initials: A
authors.lastname: Flyvbjerg
authors.forename: J
authors.initials: J
authors.lastname: Dinesen
authors.forename: H
authors.initials: H
authors.lastname: Lund
authors.forename: K G
authors.initials: KG
authors.lastname: Alberti
authors.forename: H
authors.initials: H
authors.lastname: Orskov
authors.forename: J S
authors.initials: JS
authors.lastname: Christiansen
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007018:Hypopituitarism / Q000097:blood* / Q000188:drug therapy; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000097:blood; D008297:Male; D011897:Random Allocation
chemical_list: D001786:Blood Glucose; D007328:Insulin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D005934:Glucagon